Linda L. Neuman - 14 Nov 2022 Form 3 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Chief Medical Officer
Signature
/s/ James Kastenmayer, by power of attorney
Issuer symbol
SYRE
Transactions as of
14 Nov 2022
Net transactions value
$0
Form type
3
Filing time
27 Jan 2023, 17:18:35 UTC
Next filing
24 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AGLE Common Stock 4,000 14 Nov 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGLE Employee Stock Option (right to buy) 14 Nov 2022 Common Stock 40,000 $7.82 Direct F1
holding AGLE Employee Stock Option (right to buy) 14 Nov 2022 Common Stock 30,000 $3.17 Direct F2
holding AGLE Employee Stock Option (right to buy) 14 Nov 2022 Common Stock 25,000 $1.90 Direct F3
holding AGLE Employee Stock Option (right to buy) 14 Nov 2022 Common Stock 41,250 $0.6800 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest as to 1/4th of the total shares on April 12, 2022, and then 1/48th of the shares will vest monthly thereafter, such that the option is fully vested on April 12, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on May 15, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48th of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.

Remarks:

Exhibit 24 - Power of Attorney